CMB International Securities  Equity Research Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
China Healthcare Sector
Jill Wu CFA
Sam Hu PhD
Mkt Cap (RMB mn)
Avg 3mths to (RMB mn)
52W HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
A-share public shareholders 6047%
H-share public shareholders 1290%
Source Bloomberg
Source Bloomberg
12-mth price performance
Source Bloomberg
Auditor Deloitte Touche Tohmatsu
Strong growth outlook in 2021 and
beyond  25 Jan 2021
Accelerated growth in 3Q20 driven by
strong performance in CDMO and
China-base lab service  30 Oct 2020
COVID-19 pandemic  17 Aug 2020
SHSZ300 (rebased)
1 Apr 2021
BUY (Maintain)
(Previous TP
RMB21873)
UpDownside
 Earnings slightly beat WuXi AppTec reported 2020 revenue of
RMB1654bn (29% YoY) and adjusted non-IFRS net profit of RMB356bn
(48% YoY) in line with our estimates By segment China-based lab service
and CDMO service continued strong growth momentum delivering 32% YoY
and 41% YoY revenue growth respectively contributing 52% and 32% of total
declined 3% YoY and clinical research CROSMO service growth slowed
down to 10% YoY When China-based laboratory services and CDMO
services maintained stable margins in 2020 US-based laboratory services
and clinical services experienced 87ppts and 97ppts gross margin retreat
due to COVID impact WuXi AppTec continued to expand its customer base
and added over 1300 new customers with total active customers reaching
the strong customer demand WuXi AppTec aims to further grow its employee
size from 26411 in 2020 (21% YoY) to 33600 (27% YoY) by 2021E
 Seize long-term growth opportunities by accumulating cutting-edge
expertise WuXi AppTec aims to invest in new capabilities and capacities
such as PROTAC oligonucleotide peptide ADC bi-specific antibody cell
and gene therapies to capture new business opportunities WuXi STA
(subsidiary of WuXi AppTec) and WuXi Biologics plans to form a JV focused
on ADCs and other drug conjugates With integrated platform the JV will
provide customers end-to-end CDMO services from payloadslinkers
antibodies to finished conjugated drug products under one roof In 2020 the
Company also launched China-based cell therapy product CTDMO platform
and AAV adherent and suspension manufacturing platform in China
Furthermore WuXi AppTec will further explore technologies such as AI
medical big data and laboratory automation etc With technology advantage
we believe the Company will continue to gain market share from global market
based laboratory services will grow strongly driven by capacity expansion and
to its small-molecule CDMO pipeline in 2020 and its total small-molecule
CDMO pipeline expanded to over 1300 active projects including 28
therapy CTDMO projects reached 38 projects (incl China-based operations)
of which 2-3 products are expected to file BLA in 2021 The Company
registered 41% YoY growth in its SMO backlog in 2020 and 48% YoY growth
in its CDS backlog during the same period With the ease of the pandemic
we expect clinical CRO revenue to see strong recovery in 2021E
 Maintain BUY We revised up the net profit of FY21E22E by 9%9% and
forecast the net profit to grow 52%33% YoY in FY21E22E respectively
Moreover WuXi AppTecs diversified investment portfolio will bring significant
investment gains over the long term We raised our TP to RMB21888 (WACC
934% Terminal growth rate 400%)
WuXi AppTec (603259 CH)
Building cutting-edge expertise to secure long-
1 Apr 2021
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
YoY growth (%)
YoY growth (%)
Change (%)
Consensus EPS (RMB)
Net gearing (%)
Source Company data Wind CMBIS estimates
1 Apr 2021
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 FY20A results change
YE 31 Dec (RMB mn)
Pre-tax profit
Net profit attributable to shareholders
Core net profit attributable to shareholders
Adjusted Non-IFRS attributable net profit
Source Company data CMBIS estimates
Figure 2 CMBIS earnings revisions
Source Bloomberg CMBIS estimates
Figure 3 CMBIS vs consensus
Source Bloomberg CMBIS estimates
1 Apr 2021
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 4 Risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
 of shares
DCF per share (in RMB)
Source CMBIS estimates
Figure 5 Sensitivity analysis (RMB mn)
Source Company data CMBIS estimates
1 Apr 2021
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E  YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E
China-based lab services
8546 11110 14442 18775  Depreciation and amortization
CMOCDMO services
9413 12425  Change in working capital
US-based laboratory services
2822  Investment loss (gain)
Clinical research  other
2749  Other operating activities
43  Net cash from operating
Acquisition of subsidiaries
(77)  Other investing activities
Selling  distribution expenses
(990) (1288)  Net cash from investing
Administrative expenses
RD expenses
(913) (1160) (1473)  Net proceeds from shares issued
7966  Net borrowings
Acquisition of non-controlling
Finance costs net
(69)  Dividends and interests paid
100  Other financing activities
Net gain from FV changes
1254  Net cash from financing
Pre-tax profit
(679) (1064) (1418)  Net change in cash
(70)  Cash at the beginning of the year
7964  Cash at the end of the year
YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E  YE 31 Dec
FY19A FY20A FY21E FY22E FY23E
Non-current assets
9564 10090 10543  China-based lab services
761  CMOCDMO services
9489 12538 15892  US-based laboratory services
Clinical research and other
Other non-current assets
7434  Others
12663 23059 20546 22721 26410  Profit  loss ratios (%)
8542  Gross margin
4742  EBITDA margin
Trade and bills receivables
6657  Pre-tax margin
Prepayments deposits
and other receivables
210  Net margin
6259  Effective tax rate
9541 10986  Balance sheet ratios
1230  Current ratio (x)
Trade and other payables
4007  Trade receivables turnover days
Other current liabilities
5749  Trade payables turnover days
Net debt to total equity ratio (%)
068 Net cash Net cash Net cash Net cash
Non-current liabilities
-  Returns (%)
Other non-current liabilities
5652  ROE
387  Per share
Shareholders equity
BVPS (RMB)
Source Company data CMBIS estimates
1 Apr 2021
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIS
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in
the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of CMBIS or
its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIS may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with
and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
CMBIS is not a registered broker-dealer in the United States  As a result CMBIS is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or
qualified as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA
Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report
is intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing
to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as
defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced
by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers
Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined
in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the
extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report